Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Although clinical trials specifically for MASH have not yet been conducted, preclinical studies confirm significant regulatory effects on hepatic metabolism, providing a novel strategy for targeted MASH therapy and supporting future translational research
Reported pharmacokinetic data give BPC-157 a short elimination half-life of roughly 1530 minutes in rodent and canine models, whereas TB-500 is reported with a longer serum half-life of about 2.53 hours plus prolonged tissue availability
Mechanistic case, trial data, and the open question
The scale starts moving with some consistency
The effect had not plateaued, implying weight reduction could be higher over longer durations
Prime time for peptide-based drug discovery
US$ 28.87
US$ 24.29
US$ 25.12
